Antibody Drug Conjugate (ADC) Market to Reach $28.41 Billion by 2035 | AstraZeneca, Daiichi Sankyo, Roche

The global antibody drug conjugate (ADC) market, valued at USD 15.29 billion in 2025, will grow to USD 18.69 billion in 2026 and reach USD 28.41 billion by 2035, advancing at a CAGR of 4.8% through the forecast period. With 19 approved therapies already on the market and an active clinical pipeline spanning hundreds of programs, the ADC sector has moved well past proof-of-concept and into a sustained commercial expansion phase driven by oncology demand, biotech innovation, and escalating pharmaceutical R&D investment.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/request-sample.html

Market Overview
Antibody drug conjugates are precision oncology therapeutics that attach a monoclonal antibody to a cytotoxic payload through a chemical linker. The antibody homes in on a cancer-specific antigen, delivering the toxic drug directly to the tumor and largely sparing healthy tissue, a mechanism that addresses one of the central limitations of conventional chemotherapy. This specificity has made ADCs an increasingly preferred treatment modality across both solid tumors and hematological malignancies.

Nineteen ADCs have received regulatory clearance to date, including Enhertu (Daiichi Sankyo and AstraZeneca), Kadcyla (Roche), Trodelvy (Gilead Sciences), and Padcev (Pfizer and Astellas Pharma). Enhertu alone generated approximately USD 3.75 billion in sales in 2024, signaling the commercial scale this drug class can achieve. AstraZeneca's Puja Sapra (Senior Vice President) described the company's approach directly: "We have deliberately made investment in the next-generation technologies which we believe will redefine oncology care, like ADCs and radioconjugates." That posture reflects an industry-wide conviction, not an outlier bet.

The pace of deal activity reinforces the point. In March 2025, Roche licensed two ADC candidates from Oxford BioTherapeutics, committing to lead subsequent research and development. In June 2025, Sanyou Biopharmaceuticals signed an agreement with Medicovestor to develop first-in-class chemoimmunotherapy ADCs for oncology and autoimmune indications. These transactions, alongside manufacturing partnerships such as Kivu Bioscience's agreement with Sterling Pharma Solutions for its next-generation ADC KIVU-107, reflect the speed at which new entrants and incumbents alike are moving to secure positions across the value chain.

Key Growth Drivers
Rising Cancer Incidence and Precision Medicine Demand. Cancer diagnoses continue to rise globally, and patients increasingly require therapies that can distinguish between malignant and healthy cells. ADCs address this gap directly. The growing prevalence of breast cancer, lung cancer, and hematological malignancies, which together account for the majority of approved ADC indications, is generating a structural volume tailwind that will persist through the forecast period.

Next-Generation Linker and Payload Technologies. Early ADCs faced real limitations, including premature payload release and off-target toxicity. Advances in site-specific conjugation, novel linker chemistries, and high-potency payloads are resolving these issues. The tetrapeptide-maleimide linker sub-segment, for example, is forecast to expand at a CAGR of 65.7% through 2035. Monomethyl auristatin E (MMAE) currently anchors 41% of the payload market, valued for its picomolar cytotoxicity and bystander-killing effect on antigen-negative tumor cells.

Accelerating Regulatory Approvals. The FDA has been actively reviewing and clearing ADC therapies at a pace that gives commercial-stage developers clear pathways to market. The accelerated approval granted to Datroway (a TROP2-targeting ADC) for lung cancer in June 2025, and to Emrelis (telisotuzumab vedotin-tllv) for non-squamous NSCLC in May 2025, both demonstrate that regulators are moving with the science rather than behind it.
Surge in Strategic Partnerships and Licensing Activity. The number of product licensing and technology licensing deals signed in this domain rose sharply in 2026. Large pharma companies are forging alliances to access proprietary ADC platforms, while smaller developers are using licensing revenue to fund pipeline expansion. This deal flow is accelerating development timelines across the board.

Expanding Indications Beyond Oncology. Autoimmune disease represents an emerging application area. Multiple developers are exploring ADC mechanisms to selectively deplete autoreactive immune cells, a use case distinct from traditional oncology applications. If this indication category matures, it will significantly expand the total addressable market through 2035 and beyond.

Market Segmentation
The antibody drug conjugate market segments by target indication, therapeutic area, linker type, payload, target antigen, and geography. By target indication, breast cancer commands the largest share at 44.7% of the current market, reflecting the high incidence rate and the commercial success of HER2-directed therapies such as Enhertu and Kadcyla. The lung cancer sub-segment, however, carries the highest growth trajectory through 2035, aided by recent FDA approvals and a crowded clinical pipeline.

By therapeutic area, solid tumors account for 71% of the current market and are projected to reach 76% of the future market share by 2035, as industry developers concentrate development and approval activity in this category. By payload, MMAE captures 41% of the current market. By target antigen, HER-2 directed therapies hold 48% of the current market share, while c-Met antigen-targeting ADCs are forecast to grow at the fastest rate among antigen sub-segments at a CAGR of 41.8%.

To request quote of this report, please visit: https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/request-quote.html

Regional Insights
North America leads the global antibody drug conjugate market with 62.3% of current market share, a position it will maintain through 2035. The FDA's active review calendar for ADC therapies, combined with the high incidence of cancer in the United States and the concentration of major ADC developers and CDMOs in the region, sustains this lead. More than 35% of the approximately 165 therapy developers active in the global ADC space are headquartered in North America.
Asia-Pacific is the fastest-growing regional market, forecast to expand at a CAGR of 9.8% through 2035. China, Japan, and Australia are the primary contributors to this growth, driven by a rising number of biopharmaceutical startups, an increasing volume of late-stage ADC programs in regional pipelines, and anticipated therapy approvals across the region. Mid-sized developers in Asia-Pacific with Phase III and above programs include Alphamab Oncology, CSPC Pharmaceutical, DualityBio, and Hengrui Pharma.

Competitive Landscape
The global antibody drug conjugate market features approximately 165 active therapy developers. Small companies constitute 43% of the total, followed by mid-sized players at 33% and very large companies at 14%. Among 20 commercialized ADCs, the market leaders include AbbVie, ADC Therapeutics, Astellas Pharma, AstraZeneca, Daiichi Sankyo, Gilead Sciences, GSK, Jiangsu Hengrui Pharmaceuticals, Kelun-Biotech, Merck, Pfizer, Rakuten Medical, RemeGen, and Roche. The primary competitive battleground sits at the intersection of IP, platform technology, and partnership access. Large pharma companies are securing positions through licensing deals and co-development arrangements, while mid-sized players are differentiating on linker and payload innovation. Approximately 46% of ADC therapy programs currently in development are in clinical-stage trials, with the majority at Phase II or above, signaling a near-term wave of potential approvals that will further intensify competition.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/antibody-drug-conjugates-market/270.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.